Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Adipose MSCs for COVID-19 Respiratory Compromise
NCT04352803Phase 1Not yet recruiting
- Sponsor
- Regeneris Medical
- Start
- Apr 2020
- Primary completion
- Apr 2024
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, randomised, open-label trial of autologous adipose-derived mesenchymal stromal cells in COVID-19 pneumonia and cytokine storm (CRS), sponsored by Regeneris Medical. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
COVID-19 pneumoniacytokine storm (CRS)
Beyond the preview
Go deeper on NCT04352803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04352803.